News Release

Leading artificial intelligence companies partner on a quest to solve Duchenne Muscular Dystrophy

Business Announcement

InSilico Medicine


image: Insilico Medicine announced a research collaboration agreement with A2A Pharmaceuticals, Inc. The two parties agreed to create a new company called 'Consortium.AI', which will apply the latest advances in AI to discovery of novel small molecules for the Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases. view more 

Credit: Insilico Medicine, Inc.

Thursday, July 19, 2018, Rockville, MD - Insilico Medicine a leader in artificial intelligence for drug discovery, biomarker development and aging research, announced a research collaboration agreement with A2A Pharmaceuticals, Inc. A2A is a biotechnology company headquartered in New York and focused on development of novel drugs for unmet needs in oncology, drug resistant bacterial infections, and other life threatening diseases.

The companies agreed to join forces to create a new company called “Consortium.AI” , which will apply the latest advances in AI to discovery of novel small molecules for the Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases. Computationally pre-optimized new drug candidates have already been designed for targets validated through Insilico’s artificial intelligence system A2A Pharmaceuticals will assume the management of the new company, provide the development expertise for the newly discovered compounds and should be contacted for the licensing of the compounds.

“We are pleased to partner with Insilico Medicine, combining our strengths and complementary technologies to accelerate advancement of better therapeutics into the clinic for the patients that need them.”, said Dr. Elena Diez Cecilia, Head of Business Development at A2A Pharmaceuticals. “Muscular Dystrophy is a debilitating and terminal degenerative condition that causes muscle inflammation and wasting, and there is a huge need for more effective therapies ”, she said.

Both companies will collaborate on research programs devoted to the development of therapeutic approaches for Duchenne muscular dystrophy (DMD) and other severe genetic disorders. Insilico Medicine‘s technology applies advances in deep neural networks to identifying critical disease targets and generation of novel chemistry using next-generation artificial intelligence. A2A uses proprietary computational tools including artificial intelligence to design highly selective therapeutics for difficult to drug targets like protein-protein interactions.

“A2A Pharmaceuticals has a team of highly talented drug hunters with a proven track record in discovery, development and licensing of the drug candidates. We are very happy to partner with their team to address the unmet medical needs of patients who are desperately waiting for solutions. This is fantastic application for AI ”, said Alex Zhavoronkov, founder and CEO of Insilico Medicine.

The companies agreed to collaborate on drug discovery programs, empowering Insilico AI’s biology and target discovery engine with A2A’s state-of-the-art chemical design expertise in drug development. Consortium AI will bridge the ecosystems of two rapidly expanding AI-companies to enable dramatically faster and less expensive development of more effective therapeutics.

About Insilico Medicine, Inc.

Insilico Medicine is an artificial intelligence company with R&D offices and resources in the US, Belgium, Russia, the UK, Taiwan and Korea, sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for diseases with a known ligand and with no known targets. In addition to working collaborations with large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products, compounded using advanced bioinformatics and deep learning techniques. It also provides a range of consumer-facing applications, including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies for potential in social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied by industry brief. Brief company video:

About A2A Pharmaceuticals, Inc.

A2A Pharmaceuticals Inc. is a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents for difficult-to-drug targets. Our focus is on the development of novel drugs to treat cancer, antibiotic resistant bacterial infections and other life threatening diseases. Our SCULPT technology is a fragment-based, de novo design which incorporates Artificial Intelligence in drug discovery processes that include (1) fingerprint-based protein-ligand interaction prediction, (2) Decision making machine learning, (3) Deep learning algorithms for structure-activity relationship analysis and the creation of new chemical entities.

A2A's oncology programs apply its therapeutic design methodology towards inhibiting therapeutically relevant protein-protein interactions (PPIs) and its SCULPT platform enables the design of novel ligands to specifically match the unique topological features of individual target classes. A2A's antibiotic program aims for the development of novel antibiotics against gram-negative bacterial species, utilizing various bioinformatic approaches incorporated into the SCULPT ecosystem.

A2A Pharmaceuticals won the Johnson & Johnson Innovation JLABS Artificial Intelligence quickfire challenge and takes residency at the JLABS @ NYC.

For more information visit


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.